Tag: Ipf

In clinical trials like INPULSIS and INBUILD, over 60% of patients taking nintedanib reported experiencing diarrhea, making it the most common adverse event associated with the medication [1.2.1, 1.8.5]. The question is not just *if*, but how to manage when it occurs. So, **can nintedanib cause diarrhea?** The answer is a definitive yes.

While the prognosis for idiopathic pulmonary fibrosis (IPF) has long been abysmal, with limited treatment options, a growing body of research suggests a surprising new avenue. Recent studies have investigated the potential of the common diabetes medication, metformin, and its ability to not only slow the progression of fibrosis but potentially reverse established disease.

Fibrotic diseases, characterized by organ scarring, represent a significant health burden, with idiopathic pulmonary fibrosis (IPF) being a primary example [1.2.2]. As of 2025, the key question, 'What is the new anti-fibrotic drug?', points towards nerandomilast, a promising agent nearing potential FDA approval [1.2.1, 1.2.5].

According to clinical trials, a significant number of patients on Esbriet experienced fatigue, with some studies reporting incidence rates as high as 26% compared to placebo groups. It's crucial for patients to understand if and **does Esbriet cause fatigue** and how to manage this side effect effectively.

In the United States, idiopathic pulmonary fibrosis (IPF) affects an estimated 100,000 people, with 30,000 to 40,000 new cases diagnosed annually. This article explores a key treatment: **what is the drug Esbriet used for?**